Tight glycaemic control and cardiovascular disease in type 2 diabetes.
The role of tight glycaemic control in reducing cardiovascular events and mortality in type 2 diabetes has not yet been firmly established. Recent clinical trials have yielded unexpected outcomes. This review summarizes the background and outcome of these trials and the implications for management of glycaemia in type 2 diabetes.
Demssie
Yared N
YN
Department of Diabetes and Endocrinology, Salford Royal Foundation, NHS Trust, UK.
Soran
Handrean
H
Younis
Naveed
N
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality; D003925:Diabetic Angiopathies / Q000401:mortality / Q000517:prevention & control*; D006442:Glycated Hemoglobin / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008875:Middle Aged; D012307:Risk Factors; D016896:Treatment Outcome
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human